Met Life Investment Management, LLC Intra Cellular Therapies, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 6,488 shares of ITCI stock, worth $819,174. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,488
Previous 6,615 1.92%
Holding current value
$819,174
Previous $453,000 4.64%
% of portfolio
0.0%
Previous 0.0%

Shares

50 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$67.99 - $80.84 $8,634 - $10,266
-127 Reduced 1.92%
6,488 $474,000
Q2 2024

Aug 13, 2024
SELL
$64.76 - $79.84 $2.68 Million - $3.3 Million
-41,388 Reduced 86.22%
6,615 $453,000
Q1 2024

May 14, 2024
BUY
$64.37 - $75.65 $3.09 Million - $3.63 Million
48,003 New
48,003 $3.32 Million
Q3 2023

May 09, 2024
BUY
$52.09 - $64.1 $78,082 - $96,085
1,499 Added 3.13%
49,370 $2.57 Million
Q2 2023

Apr 29, 2024
BUY
$54.67 - $66.44 $2.7 Million - $3.28 Million
49,370 New
49,370 $3.13 Million
Q2 2023

Aug 10, 2023
BUY
$54.67 - $66.44 $81,950 - $99,593
1,499 Added 3.13%
49,370 $3.13 Million
Q1 2023

May 09, 2024
BUY
$43.8 - $56.99 $2.1 Million - $2.73 Million
47,871 New
47,871 $2.59 Billion
Q1 2023

May 15, 2023
SELL
$43.8 - $56.99 $37,054 - $48,213
-846 Reduced 1.74%
47,871 $2.59 Million
Q4 2022

Jun 14, 2023
BUY
$44.07 - $54.45 $37,283 - $46,064
846 Added 1.77%
48,717 $2.58 Million
Q3 2022

May 10, 2024
BUY
$42.7 - $59.99 $48,464 - $68,088
1,135 Added 2.39%
48,717 $2.27 Million
Q3 2022

Jun 14, 2023
BUY
$42.7 - $59.99 $36,124 - $50,751
846 Added 1.77%
48,717 $2.27 Million
Q3 2022

Mar 22, 2023
BUY
$42.7 - $59.99 $48,464 - $68,088
1,135 Added 2.39%
48,717 $2.27 Million
Q3 2022

Nov 14, 2022
BUY
$42.7 - $59.99 $48,464 - $68,088
1,135 Added 2.39%
48,717 $2.27 Million
Q2 2022

May 10, 2024
BUY
$43.0 - $65.64 $217,881 - $332,597
5,067 Added 11.92%
47,582 $2.72 Million
Q2 2022

Jun 20, 2023
SELL
$43.0 - $65.64 $12,427 - $18,969
-289 Reduced 0.6%
47,582 $2.72 Million
Q2 2022

Mar 22, 2023
BUY
$43.0 - $65.64 $217,881 - $332,597
5,067 Added 11.92%
47,582 $2.72 Million
Q2 2022

Aug 11, 2022
BUY
$43.0 - $65.64 $217,881 - $332,597
5,067 Added 11.92%
47,582 $2.72 Million
Q1 2022

May 10, 2024
BUY
$38.74 - $62.09 $1.65 Million - $2.64 Million
42,515 New
42,515 $2.6 Million
Q1 2022

Jun 20, 2023
SELL
$38.74 - $62.09 $207,491 - $332,554
-5,356 Reduced 11.19%
42,515 $2.6 Million
Q1 2022

Mar 22, 2023
BUY
$38.74 - $62.09 $703,518 - $1.13 Million
18,160 Added 74.56%
42,515 $2.6 Million
Q1 2022

May 12, 2022
BUY
$38.74 - $62.09 $703,518 - $1.13 Million
18,160 Added 74.56%
42,515 $2.6 Million
Q4 2021

May 17, 2024
SELL
$35.2 - $53.42 $74,307 - $112,769
-2,111 Reduced 7.98%
24,355 $1.27 Million
Q4 2021

Jun 21, 2023
SELL
$35.2 - $53.42 $827,763 - $1.26 Million
-23,516 Reduced 49.12%
24,355 $1.27 Million
Q4 2021

Mar 22, 2023
SELL
$35.2 - $53.42 $74,307 - $112,769
-2,111 Reduced 7.98%
24,355 $1.27 Million
Q4 2021

Feb 15, 2022
SELL
$35.2 - $53.42 $74,307 - $112,769
-2,111 Reduced 7.98%
24,355 $1.28 Million
Q3 2021

Jun 21, 2023
SELL
$28.72 - $42.49 $614,751 - $909,498
-21,405 Reduced 44.71%
26,466 $986,000
Q2 2021

Jun 21, 2023
SELL
$29.3 - $44.5 $627,166 - $952,522
-21,405 Reduced 44.71%
26,466 $1.08 Million
Q1 2021

May 17, 2024
SELL
$30.8 - $39.51 $663,339 - $850,926
-21,537 Reduced 44.87%
26,466 $897,000
Q1 2021

Jun 26, 2023
SELL
$30.8 - $39.51 $659,274 - $845,711
-21,405 Reduced 44.71%
26,466 $898 Million
Q4 2020

Jun 22, 2023
SELL
$23.34 - $32.22 $499,592 - $689,669
-21,405 Reduced 44.71%
26,466 $841,000
Q3 2020

Jun 26, 2023
SELL
$17.61 - $31.86 $376,942 - $681,963
-21,405 Reduced 44.71%
26,466 $679,000
Q2 2020

May 24, 2024
SELL
$14.35 - $26.64 $309,055 - $573,745
-21,537 Reduced 44.87%
26,466 $679 Million
Q2 2020

Jun 26, 2023
SELL
$14.35 - $26.64 $307,161 - $570,229
-21,405 Reduced 44.71%
26,466 $679,000
Q2 2020

Mar 22, 2023
BUY
$14.35 - $26.64 $45,934 - $85,274
3,201 Added 13.76%
26,466 $679,000
Q2 2020

Aug 14, 2020
BUY
$14.35 - $26.64 $45,934 - $85,274
3,201 Added 13.76%
26,466 $679,000
Q1 2020

Jul 12, 2023
SELL
$12.31 - $33.12 $302,899 - $814,950
-24,606 Reduced 51.4%
23,265 $357,000
Q1 2020

Mar 22, 2023
BUY
$12.31 - $33.12 $45,042 - $121,186
3,659 Added 18.66%
23,265 $357,000
Q1 2020

May 15, 2020
BUY
$12.31 - $33.12 $45,042 - $121,186
3,659 Added 18.66%
23,265 $358,000
Q4 2019

Jul 12, 2023
SELL
$7.26 - $38.49 $205,203 - $1.09 Million
-28,265 Reduced 59.04%
19,606 $672,000
Q3 2019

Jul 12, 2023
SELL
$7.47 - $14.03 $211,139 - $396,557
-28,265 Reduced 59.04%
19,606 $146,000
Q2 2019

Jul 12, 2023
SELL
$10.65 - $14.29 $301,022 - $403,906
-28,265 Reduced 59.04%
19,606 $254,000
Q1 2019

Jul 13, 2023
SELL
$10.9 - $14.09 $308,088 - $398,253
-28,265 Reduced 59.04%
19,606 $238,000
Q4 2018

Jul 13, 2023
SELL
$10.36 - $20.96 $292,825 - $592,434
-28,265 Reduced 59.04%
19,606 $223,000
Q4 2018

Mar 22, 2023
SELL
$10.36 - $20.96 $113,276 - $229,176
-10,934 Reduced 35.8%
19,606 $223,000
Q4 2018

Feb 14, 2019
SELL
$10.36 - $20.96 $113,276 - $229,176
-10,934 Reduced 35.8%
19,606 $223,000
Q3 2018

Jul 13, 2023
SELL
$17.77 - $22.9 $502,269 - $647,268
-28,265 Reduced 59.04%
19,606 $425,000
Q3 2018

Mar 22, 2023
SELL
$17.77 - $22.9 $323,005 - $416,253
-18,177 Reduced 37.31%
30,540 $662,000
Q3 2018

Nov 14, 2018
BUY
$17.77 - $22.9 $194,297 - $250,388
10,934 Added 55.77%
30,540 $663,000
Q1 2018

May 15, 2018
BUY
$15.16 - $25.49 $39,613 - $66,605
2,613 Added 15.38%
19,606 $413,000
Q4 2017

Feb 15, 2018
BUY
$14.27 - $16.79 $242,490 - $285,312
16,993
16,993 $246,000

Others Institutions Holding ITCI

# of Institutions
381
Shares Held
84M
Call Options Held
319K
Put Options Held
143K
View Full List

About Intra-Cellular Therapies, Inc.

ITCI Quotes by TradingView
  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $11.9B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email